Document is current

Any future updates will be listed below

Correction to: A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1)

Crossref DOI link: https://doi.org/10.1007/s12185-023-03584-0

Published Online: 2023-03-21

Published Print: 2023-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark